Comments
Jubilant Life Sciences has received final approval from the US health regulator for olmesartan medoxomil tablets used in the treatment of hypertension.
The company said in a BSE filing that it has received abbreviated new drug application (ANDA) final approval for olmesartan medoxomil tablets — 5 mg, 20 mg, and 40 mg.
The approved product is the generic version of Benicar of Daiichi Sankyo which is used for the treatment of hypertension.
As on December 31, 2016, Jubilant Life Sciences had 73 ANDAs for oral solids filed in the US, of which 49 have been approved.
The company shares were trading at Rs 827.50, up 4.72 per cent on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.